Akonni's $3M Grant Latest in String of NIH Awards for PCR Array-Based Infectious Disease Dxs

A company official said that Akonni's technology, which combines the power of real-time PCR interrogation with microarray analysis, is well-suited to address the emergence of drug resistance and the need to interrogate a broader range of markers in infectious disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.